Table 1 Association study in the first stage, second stage and combined stage.

From: Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study

Chr.

SNP (position*)

Study group

TiA

GD controls

   

n

RAF

OR †

(95% CI)

P value ‡

n

RAF

OR † (95% CI)

6

HLA-B*38:02 (31323319)

First stage

21

0.238

7.42

(3.47–15.90)

1.59 × 10−09

656

0.040

1.00

  

Second stage

21

0.357

21.91

(10.48–45.83)

1.59 × 10−27

546

0.025

1.00

  

Combined stage

42

0.298

12.31

(7.33–20.67)

6.75 × 10−32

1202

0.033

1.00

6

rs17193122 (31335336)

First stage

21

0.262

5.74

(2.74–12.02)

8.18 × 10−08

474

0.058

1.00

  

Second stage

21

0.381

16.77

(8.20–34.30)

1.15 × 10−24

453

0.035

1.00

  

Combined stage

42

0.321

9.59

(5.78–15.90)

4.29 × 10−27

927

0.047

1.00

6

rs116869525 (32389143)

First stage

21

0.262

4.66

(2.24–9.67)

3.88 × 10−05

474

0.071

1.00

  

Second stage

21

0.286

3.77

(1.86–7362)

8.24 × 10−05

453

0.096

1.00

  

Combined stage

42

0.274

4.16

(2.50–6.90)

1.27 × 10−08

927

0.083

1.00

6

HLA-DRB1*08:03 (32552080)

First stage

21

0.286

4.76

(2.36–9.57)

1.24 × 10−05

651

0.078

1.00

  

Second stage

21

0.286

3.96

(1.97–7.98)

3.91 × 10−05

545

0.092

1.00

  

Combined stage

42

0.286

4.36

(2.66–7.15)

1.83 × 10−09

1196

0.084

1.00

  1. Chr., chromosome; CI, confidence interval; GD, Graves’ Disease; HLA, human leukocyte antigen; OR, odds ratio; RAF, risk allele frequency; TiA, thionamide-induced agranulocytosis.
  2. *The physical positions were annotated according to NCBI build 37.1.
  3. †OR values were calculated using allelic association test.
  4. ‡P values were calculated using Cochran–Armitage test for trend.
Back to article page